Kornimate/medical-research-clean huggingface dataset:
vascular occlusion in patients with osteoarthritis

Conditions: Osteoarthritis

Summary: resistance exercise plus vascular occlusion may induce greater improvements in strength and muscle mass than resistance training alone. the investigators speculate this training strategy could be beneficial in patients with osteoarthritis.


Eligibility criteria:
inclusion criteria: * postmenopausal women * bmi \<39 * knee ostearthritis type ii and iii * vas (visual analogue scale) between 2 and 8 exclusion criteria: * hip osteoarthritis * use of nsaid
a study to evaluate safety and efficacy of bomedemstat (mk-3543-017)

Conditions: Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera

Summary: the primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. the study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * participants from the img-7289-202/mk-3543-005 (nct05223920) study must have received at least 6 months of treatment with bomedemstat; * essential thrombocythemia (et) and polycythemia vera (pv) participants from studies other than img-7289-202/mk-3543-005 must have achieved confirmed hematologic remission. no hypothesis testing will be conducted in this study.


Eligibility criteria:
inclusion criteria: * is from a bomedemstat study sponsored by imago biosciences, inc. (a subsidiary of merck \& co., inc.) or msd, and established by the sponsor as mk-3543-017 ready * has received at least 6 months of treatment with bomedemstat in the img-7289-202/mk-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator * et and pv participants from established feeder studies other than img-7289- 202/mk-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator * is not currently on a dose hold * participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat exclusion criteria: * has received prohibited concomitant medications * ongoing or planned participation in another investigational study * has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as assigned by the investigator
barrett's esophagus & gastroesophageal reflux disease

Conditions: Barrett's Esophagus; GERD

Summary: this is a study of barrett's esophagus (be) and gastroesophageal reflux disease (gerd). it aims to look at the long term efficacy of evidence-based cutting edge diagnostic and therapeutic algorithms and techniques such as radiofrequency ablation, endoscopic mucosal resection and surveillance endoscopy with biopsy. additionally, biological analyses will be performed in hopes of identifying biomarkers associated with the progression of be to esophageal cancer.

barrett's esophagus (be) is a known premalignant condition of the esophagus, predisposing to the development of esophageal adenocarcinoma. be represents a change in the lining (mucosa) of the esophagus which is known to be produced as a result of chronic gastroesophageal reflux. the current standard of care for patients with be includes serial performance of upper endoscopy with multiple biopsies, performed at designated time intervals. however, the emergence of new technologies for the management of this condition has made the care of these patients non-uniform, and subject to biases of individual treating physicians. the protocol at the valley hospital and blumenthal cancer center aims to standardize the management of patients with barrett's esophagus, with and without dysplasia, using evidence-based, cutting edge diagnostic and therapeutic algorithms and techniques such as radiofrequency ablation, endoscopic mucosal resection, and surveillance endoscopy with biopsies. if biopsies suggest the development of carcinoma or high grade dysplasia surgical removal of the esophagus is recommended. this study aims to look at the long-term efficacy of these procedures. in addition, data regarding clinical outcomes will be collected as well as blood, tissue and surgical specimens for proteomic analysis in hopes of identifying biomarkers associated with the progression of dysplasia to adenocarcinoma. although patients will ultimately make their own informed decisions regarding the management of their be, this protocol serves to unify physician recommendations, and allows for the collection and interpretation of data.

Eligibility criteria:
inclusion criteria: * male or female, age 18 to 85. * patient must have barrett's esophagus. patients may be enrolled based on previous endoscopy reports and/or pathology reports. it is not necessary that each patient have endoscopy for the sole purpose of enrollment. * must agree to allow their clinical information to be collected, stored, analyzed and reported. * must allow portions of their biopsy/surgical specimens to be collected, stored, analyzed and reported. * must agree to fill out patient questionnaires in conjunction with the research study assistant assigned to this protocol (either in person or via telephone contact) at designated timepoints. exclusion criteria: * intestinal metaplasia of the cardia, without an esophageal columnar lining. * unable to provide informed consent. * unable or unwilling to undergo endoscopic procedures.

Keywords: barrett's esophagus gerd carcinoma
autologous cytokine-induced killer cells combined chemotherapy in advanced pancreatic cancer

Conditions: Advanced Cancer

Summary: the purpose of this study is to determine whether cytokine induced killer cells combined chemotherapy is more effective in the treatment of advanced pancreatic cancer.

pancreatic cancer is a devastating malignant disease with a median survival of 3-6 months and a 5-year survival rate of less than 5%. it is necessary to explore more treatment mode to pancreatic cancer especially advanced stage patients. this study is a prospective, randomized, open, single center phase ii study. the investigators try to evaluate the efficacy and safety of this treatment mode.

Eligibility criteria:
inclusion criteria: 1. no less than 18 years old 2. karnofsky performance status over 60 3. life expectancy more than three months 4. pathological diagnosed as pancreatic epithelial cell carcinoma 5. recurrence after surgery or unresectable 6. no experienced chemotherapy or the interval between the last adjuvant chemotherapy and relapse is at least 6 months 7. measurable lesions (by ct or mri) 8. no serious mental disorders 9. adequate organ and bone marrow functions 10. no other serious and the conflict diseases(such as autoimmune diseases, immunodeficiency, organ transplantation) 11. no other malignant tumor history 12. informed consent and willing to participate in this study exclusion criteria: 1. received immunosuppressants or glucocorticoid treatment 2. uncontrolled severe infection or unhealed wound caused by suppurative inflammation 3. heart disease, insufficient heart function, ii degree heart block or occurred myocardial infarction in 6 months 4. poor pulmonary functions caused by interstitial lung disease and pulmonary reserve volume under 80% of the expected value 5. other malignant tumor history 6. transaminase\>2.5uln or bilirubin\>3uln or creatinine \>1.25uln 7. pregnant or lactating women 8. obvious bleeding tendency 9. participated other clinical trails in 1 month 10. other unsuitable conditions: hiv infection, intravenous drug abusers, etc

Keywords: cik chemotherapy pancreatic cancer
combined metformin and clomiphene citrate (cc) or laparoscopic ovarian diathermy for women with cc resistant polycystic ovary syndrome (pcos)

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this study is to compare and determine the efficacy of combined metformin and clomiphene citrate administration to that of laparoscopic ovarian diathermy (lod) in infertile women with polycystic ovary syndrome (pcos) not responding to treatment with clomiphene alone.

all patients in the combined metformin-cc group received metformin hcl (cidophage®;chemical industries development,cairo, egypt), 500 mg thrice daily for 6-8 weeks. then after the end of this period, they received 100 mg cc (clomid®; global napi pharmaceuticals,cairo, egypt) for 5 days starting from day 3 of menstruation (increased by 50 mg in the next cycle in case of anovulation ). patients continued treatment for up to six cycles. metformin was stopped only when pregnancy was documented. all patients in the control group underwent laparoscopic ovarian diathermy, then followed up for 6 months.

Eligibility criteria:
inclusion criteria: * cc resistant pcos exclusion criteria: * congenital adrenal hyperplasia * cushing syndrome * androgen secreting tumors

Keywords: polycystic ovary syndrome clomiphene resistance metformin laparoscopic ovarian diathermy
probiotic bacteria to infants with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the objective of the study is to examine whether 8 weeks intervention with probiotics influence the eczema in infants suffering from atopic dermatitis. furthermore the influence of the immunologic status and the intestinal microflora, inflammation and permeability will be investigated.

the aim of the study is to investigate whether two different probiotics influence the clinical and subjective symptoms in infants with atopic dermatitis (ad). the influence on the immunologic status and the intestinal microflora, inflammation and permeability will also be investigated. sixty two infants (6 to 24 months of age) suffering from ad will be randomised in 3 groups receiving either lactobacillus acidophilus ncfm (1x10\^10 colony forming units), bifidobacterium lactis bi-07(1x10\^10 colony forming units) or placebo every day for 8 weeks. at the beginning and at the end of the study the following analyses will be made: 1. scoring atopic dermatitis (scorad) index to describe the extent and severity of the eczema, and to describe the subjective symptoms. 2. blood samples will be drawn to examine: * immunoglobulin e (ige), total and specific for egg and milk. * eosinophil cation protein (ecp) * interleukin-10 (il-10), interleukin-12 (il-12) and interferon-gamma (ifn-gamma) 3. fecal samples will be collected to examine: * calprotectin (intestinal inflammation) * bacterial deoxyribonucleic acid (dna) will be extracted in order to perform polymerase chain reaction (pcr) analysis.

Eligibility criteria:
inclusion criteria: * atopic dermatitis exclusion criteria: * chronic diseases other than atopic dermatitis * chronic medication

Keywords: infants atopic dermatitis scorad ige eosinophil cation protein calprotectin intestinal microflora
efficacy of an encapsulated probiotic bifidobacterium infantis 35624 in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study was to determine the dose-ranging efficacy and safety profile of encapsulated bifidobacterium infantis 35624 in female subjects with irritable bowel syndrome (ibs).

the pathogenesis of irritable bowel syndrome (ibs) may have a a post-infectious inflammatory component, suggesting that altered gut bacterial flora are of relevance and that probiotics may be beneficial. this clinical trial examined the efficacy of an encapsulated probiotic in subjects with rome ii ibs. after a 2 week baseline, 362 female subjects were randomized to placebo or one of three doses of b. infantis 35624 once daily for 4 weeks. ibs symptoms were monitored daily and scored according to a 6-point likert scale; stool frequency and form were also monitored daily. the primary efficacy variable was the abdominal pain score; secondary efficacy variables included other ibs symptom relief and quality of life.

Eligibility criteria:
inclusion criteria: * meet rome ii criteria for the diagnosis of ibs * refrain from using probiotic supplements during the trial exclusion criteria: * organic diseases, including inflammatory bowel disease, and significant systemic diseases * subjects over 55 years of age that had not had a sigmoidoscopy or colonoscopy performed in the previous five years * use of anti-psychotic medications within the prior three months * had major psychiatric disorder (dsm-ii-r or dsm-iv), including major depression, psychoses, alcohol or substance abuse, within the past two years * were pregnant or nursing * had known lactose intolerance or immunodeficiency * had undergone any abdominal surgery, with the exception of hernia repair or appendectomy
clinical utility of ctc test in medicare-eligible metastatic breast cancer patients

Conditions: Metastatic Breast Cancer; Breast Cancer

Summary: the objective of the registry study is to demonstrate the clinical utility of the cellsearch® ctc test among the medicare-eligible metastatic breast cancer (mbc) patients in the united states. the objective of the present registry is to demonstrate the impact on patient management of the cellsearch® ctc test among the medicare-eligible mbc patients. hereto the hypothesis that the availability of ctc information provides clinicians important, timely information and impacts treatment decisions, will be tested. this study is ide-exempt since cellsearch® ctc test is a legally marketed device in the us, and is being used in accordance with its labeling.


Eligibility criteria:
inclusion criteria: patient has documented (histologically/pathologically confirmed) mbc diagnosis * patient is at least 65 years of age at time of mbc diagnosis * patient is male or female * patient is being actively treated at the cancer center by a physician who uses or plans to use ctc testing on his mbc patients at lease every quarter. exclusion criteria: * patients breast cancer is secondary not primary

Keywords: cellsearch ctc metastatic breast cancer registry mbc
allogeneic bone-patellar tendon-bone transplantation

Conditions: Anterior Cruciate Ligament Rupture

Summary: objective to investigate the mid-term clinical effect of bone-patellar tendon-bone (bptb) graft double-bundle reconstruction of the anterior cruciate ligament (acl) of the knee joint under arthroscope.

the purpose of the present study was to report a unique technique of double-bundle anterior cruciate ligament reconstruction (db-aclr) with a bone-patellar tendon- bone (bptb) allograftand compare the clinical outcome of the new technique with that of the nonanatomic conventional transtibial single-bundle anterior cruciate ligament reconstruction (sb-aclr) with a bptb allograft. the hypothesis was that the db-aclr with a bptb allograft is technically feasible and may be superior in restoring anterior and rotational stability of the knee joint. meanwhile, the back-pushing kt- 2000 arthrometer was used to confirm whether there were advantages of db-aclr in total anteroposterior stability.

Eligibility criteria:
inclusion criteria: from july 2005 to june 2008, 3757 aclrs were performed in our department. a total of 111 patients chose to use allografts, and the other patients chose autologous semitendinosus and gracilis tendons (stgs). the patients selected db or sb reconstruction based on their understanding about the information from the surgeons. following the criteria of a prospective randomized study, 56 patients undergoing aclrs with bptb allografts were included in our study and were divided into a db group and a sb group, each with 28 patients. 25 db and 27 sb patients completed the final follow-up. only patients between 16 and 50 years old who were undergoing primary operation were included, and younger patients had to have radiographic confirmation of a closed epiphysis. exclusion criteria: the exclusion criteria included age more than 50 years, narrow middle intercondylar width (\<12 mm measured during operation with the knee flexed to 90°), revision reconstruction, multiligament injury, bilateral aclrs, total meniscectomy or more than one-third partial meniscectomy, and severe cartilage injury.
magnetic field therapy versus transcutaneous electrical nerve-stimulation in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the effectiveness of pemf in improving physical function among osteoarthritic (oa) patients remains a topic of debate, leading to the american college of rheumatology not yet endorsing its use in oa treatment. therefore, it's essential to investigate pemf therapy's efficacy in alleviating joint pain, stiffness, and enhancing physical function in knee oa patients our study objectives were to evaluate the effectiveness and safety of pemf therapy and to compare its efficacy with tens in knee oa management.


Eligibility criteria:
inclusion criteria: * we included patients who had knee pain due to knee oa diagnosed according to the american college of rheumatology including: * knee pain and presence of at least three of the following 6 criteria: * age \> 50 years * morning stiffness \< 30 minutes * crepitus during movement * periarticular bone pain * periarticular bone hypertrophy * absence of increased local warmth. exclusion criteria: * for both groups, we did not include: * patients with a pacemaker, implantable defibrillator, cochlear implant, or any metal implant contraindicating mri (knee prosthesis, hip prosthesis, etc.). * pregnant women * patients with an active infection * profound hypoesthesia or thermoalgic sensitivity disorder * poorly vascularized areas: arteritis, phlebitis, ischemia * patients on anti-vitamin k treatment or with a coagulation disorder. patients with long-term corticosteroid therapy or having a total knee replacement, those who have received therapies for knee osteoarthritis including intra-articular corticosteroid injection or viscosupplementation in the last 4 months, and patients with knee pain of non-osteoarthritic origin were also not included in the study.
using a targeted cancer vaccine (galinpepimut-s) with immunotherapy (nivolumab) in mesothelioma

Conditions: Mesothelioma; Pleural Mesothelioma; Wilms Tumor

Summary: the purpose of this study is to test whether it is safe to give galinpepimut-s and nivolumab together in patients with mesothelioma.


Eligibility criteria:
inclusion criteria: * age \>/= 18 years * karnofsky performance status \>/= 70% * pathologic diagnosis of malignant pleural mesothelioma at msk * positive immunohistochemical staining for wt-1 within 60 days of treatment start * patients must have received at least one prior course of pemetrexed-based chemotherapy * patients of childbearing potential must have a negative serum pregnancy test within 24 hours of receiving the first treatment on the study (if female) and must be practicing an effective form of birth control for the entire duration of treatment (both females and males) * has received and progressed or are refractory to pemetrexed based chemotherapy * measurable or evaluable disease * biochemical parameters: total bilirubin \< 1.5 mg/dl, ast and alt \< 3.0 x upper limits of normal, creatinine \< 1.5 x upper limits of normal exclusion criteria: * pregnant or lactating women * prior receipt of checkpoint inhibition * patients with known active hepatitis b or known active hepatitis c virus * patients with a serious unstable medical illness or another active cancer * patients with known history of testing positive for human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome (aids) * autoimmune disease requiring treatment with systemic steroids in the past 2 years * current use of systemic corticosteroids at doses greater than prednisone 10 mg daily or the equivalent * patients with active pneumonitis * hematologic parameters: absolute neutrophil count \>/= 1000/mcl * platelet count \<100,000

Keywords: mesothelioma pleural mesothelioma wilms tumor protein 1 wt1 galinpepimut-s montanide nivolumab phase i 17-654 memorial sloan kettering cancer center
a study of the efficacy and safety of corifollitropin alfa (mk-8962) in combination with human chorionic gonadotropin (hcg) in adult men with hypogonadotropic hypogonadism (hh) (p07937)

Conditions: Hypogonadism; Hypogonadotropic Hypogonadism

Summary: this study will assess if corifollitropin alfa (mk-8962), when administered in combination with human chorionic gonadotropin (hcg), will increase testicular volume in men with hh who remain azoospermic after treatment with hcg alone. hypothesis: the lower limit of the 95% confidence interval for the geometric mean increase in testicular volume from day 1 to week 52 is greater than one.


Eligibility criteria:
inclusion criteria: * diagnosed with hypogonadotropic hypogonadism, either congenital or acquired * have low circulating levels of testosterone * have low circulating levels of gonadotropins (follicle stimulating hormone \[fsh\]; luteinizing hormone) * presence of both scrotal testes * have azoospermia (no measurable level of sperm) * adequate replacement of other pituitary hormones * good general physical and mental health exclusion criteria: * primary hypogonadism, such as klinefelter's syndrome * history of unilateral or bilateral cryptorchidism (maldescended testes) * history or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage iii, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy * treated with fsh, hcg or gonadotropin-releasing hormone (gnrh) within previous 3 months or for more than 1 month within previous 6 months * proven spermatogenesis with hcg treatment alone * previous unsuccessful attempt with hcg in combination with human menopausal gonadotropin (hmg)/fsh to achieve spermatogenesis * required a dose of hcg of more than 6000 international units (iu) per week in a previous attempt to normalize t levels * untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study * history or presence (known or suspected) of testicular, prostatic or breast cancer * prostate pathology of clinical importance * past or present oncologic treatment (chemo/radiotherapy) * diabetes mellitus * clinically significant, untreated hyperprolactinaemia * uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders) * tested positive for human immunodeficiency virus (hiv), hepatitis b or hepatitis c * user of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption * allergy/sensitivity to gonadotropins or its/their excipients * has received within previous 1 month or plans to use: hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic * used any investigational drugs within three months or actively participating in another study